At the news
? NEUTRALIMPACT 4/10 EFFECT filed Apr 7, 2026 at 00:15 ET
Pliant Therapeutics' $300 million shelf registration, including a $50 million at-the-market (ATM) offering program, has become effective. The company can now sell securities from time to time over the next three years, creating potential for future dilution.
- Shelf registration (Form S-3) has become effective, allowing Pliant Therapeutics to raise up to $300 million in capital over the next three years.
- Of the $300 million, $50 million is designated for an at-the-market (ATM) offering program with Leerink Partners LLC.
- Securities offered may include common stock, preferred stock, debt, units, and warrants, with specific terms disclosed in future prospectus supplements.
- The effectiveness allows the company to access capital markets opportunistically, but no immediate offering has been announced.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access